HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen

Lisa Rimsza, Pedro Farinha, Deborah A. Fuchs, Hamid Masoudi, Joseph M. Connors, Randy D. Gascoyne

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Loss of major histocompatibility class II (MHC class II) molecules on diffuse large B-cell lymphoma (DLBCL) has been associated with poor survival; however, none of these reports analysed a uniformly treated patient cohort. This study was designed to validate one MHC class II antigen, HLA-DR, as a prognostic marker in patients uniformly treated with the MACOP-B regimen. Immunostaining results were correlated with the international prognostic index (IPI) score and overall survival (OS). Of the 97 cases, 82 had interpretable staining. Of these, 52 expressed HLA-DR (median OS, 16.2 years) while 30 were negative (median OS, 4.2 years, P = 0.037). The IPI was also predictive of OS in the study group (P = 0.023). A Cox multivariate model established both IPI (P = 0;0.031) and HLA-DR (P = 0.04) as independent predictors of OS. This is the first demonstration of the prognostic relevance of HLA-DR in a uniformly treated DLBCL patient group.

Original languageEnglish (US)
Pages (from-to)542-546
Number of pages5
JournalLeukemia and Lymphoma
Volume48
Issue number3
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
HLA-DR Antigens
Drug Therapy
Survival
Proteins
Histocompatibility
Histocompatibility Antigens Class II
Proportional Hazards Models
MACOP-B regimen
Staining and Labeling

Keywords

  • Diffuse large B-cell lymphoma
  • HLA-DR
  • Major histocompatibility
  • Survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen. / Rimsza, Lisa; Farinha, Pedro; Fuchs, Deborah A.; Masoudi, Hamid; Connors, Joseph M.; Gascoyne, Randy D.

In: Leukemia and Lymphoma, Vol. 48, No. 3, 03.2007, p. 542-546.

Research output: Contribution to journalArticle

Rimsza, Lisa ; Farinha, Pedro ; Fuchs, Deborah A. ; Masoudi, Hamid ; Connors, Joseph M. ; Gascoyne, Randy D. / HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen. In: Leukemia and Lymphoma. 2007 ; Vol. 48, No. 3. pp. 542-546.
@article{55ad7e35057145c6a0fb9ef41ef202b1,
title = "HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen",
abstract = "Loss of major histocompatibility class II (MHC class II) molecules on diffuse large B-cell lymphoma (DLBCL) has been associated with poor survival; however, none of these reports analysed a uniformly treated patient cohort. This study was designed to validate one MHC class II antigen, HLA-DR, as a prognostic marker in patients uniformly treated with the MACOP-B regimen. Immunostaining results were correlated with the international prognostic index (IPI) score and overall survival (OS). Of the 97 cases, 82 had interpretable staining. Of these, 52 expressed HLA-DR (median OS, 16.2 years) while 30 were negative (median OS, 4.2 years, P = 0.037). The IPI was also predictive of OS in the study group (P = 0.023). A Cox multivariate model established both IPI (P = 0;0.031) and HLA-DR (P = 0.04) as independent predictors of OS. This is the first demonstration of the prognostic relevance of HLA-DR in a uniformly treated DLBCL patient group.",
keywords = "Diffuse large B-cell lymphoma, HLA-DR, Major histocompatibility, Survival",
author = "Lisa Rimsza and Pedro Farinha and Fuchs, {Deborah A.} and Hamid Masoudi and Connors, {Joseph M.} and Gascoyne, {Randy D.}",
year = "2007",
month = "3",
doi = "10.1080/10428190601078605",
language = "English (US)",
volume = "48",
pages = "542--546",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen

AU - Rimsza, Lisa

AU - Farinha, Pedro

AU - Fuchs, Deborah A.

AU - Masoudi, Hamid

AU - Connors, Joseph M.

AU - Gascoyne, Randy D.

PY - 2007/3

Y1 - 2007/3

N2 - Loss of major histocompatibility class II (MHC class II) molecules on diffuse large B-cell lymphoma (DLBCL) has been associated with poor survival; however, none of these reports analysed a uniformly treated patient cohort. This study was designed to validate one MHC class II antigen, HLA-DR, as a prognostic marker in patients uniformly treated with the MACOP-B regimen. Immunostaining results were correlated with the international prognostic index (IPI) score and overall survival (OS). Of the 97 cases, 82 had interpretable staining. Of these, 52 expressed HLA-DR (median OS, 16.2 years) while 30 were negative (median OS, 4.2 years, P = 0.037). The IPI was also predictive of OS in the study group (P = 0.023). A Cox multivariate model established both IPI (P = 0;0.031) and HLA-DR (P = 0.04) as independent predictors of OS. This is the first demonstration of the prognostic relevance of HLA-DR in a uniformly treated DLBCL patient group.

AB - Loss of major histocompatibility class II (MHC class II) molecules on diffuse large B-cell lymphoma (DLBCL) has been associated with poor survival; however, none of these reports analysed a uniformly treated patient cohort. This study was designed to validate one MHC class II antigen, HLA-DR, as a prognostic marker in patients uniformly treated with the MACOP-B regimen. Immunostaining results were correlated with the international prognostic index (IPI) score and overall survival (OS). Of the 97 cases, 82 had interpretable staining. Of these, 52 expressed HLA-DR (median OS, 16.2 years) while 30 were negative (median OS, 4.2 years, P = 0.037). The IPI was also predictive of OS in the study group (P = 0.023). A Cox multivariate model established both IPI (P = 0;0.031) and HLA-DR (P = 0.04) as independent predictors of OS. This is the first demonstration of the prognostic relevance of HLA-DR in a uniformly treated DLBCL patient group.

KW - Diffuse large B-cell lymphoma

KW - HLA-DR

KW - Major histocompatibility

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=33947660517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947660517&partnerID=8YFLogxK

U2 - 10.1080/10428190601078605

DO - 10.1080/10428190601078605

M3 - Article

VL - 48

SP - 542

EP - 546

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3

ER -